• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

July 12, 2021
Company Drug/Device Medical Condition Status
Agenus

Bristol Myers Squibb
AGEN1777 advanced solid tumors IND approved by the FDA
Cullinan Oncology CLN-619 solid and liquid tumors IND approved by the FDA
Eucure Biopharma YH001 advanced nonsmall-cell lung cancer and hepatocellular carcinoma IND approved by the FDA for phase 2 trial
Eucure Biopharma YH003 PD-1-resistant unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma IND approved by the FDA for phase 2 trial
HDT Bio HDT-301 COVID-19 RNA vaccine SARS-CoV-2 and variants IND approved by the FDA
Immunic IMU-838 relapsing-remitting multiple sclerosis IND approved by the FDA for phase 3 trial
Immunic IMU-838 progressive multiple sclerosis IND approved by the FDA for phase 2 trial
Sirnaomics STP707 advanced solid tumors IND approved by the FDA
Sorrento Therapeutics Resiniferatoxin (RTX) moderate-to-severe pain from osteoarthritis of the knee IND approved by the FDA for phase 2 trial
Vect-Horus

RadioMedix
68Ga-RMX-VH glioblastoma multiforme diagnostic exploratory IND approved by the FDA
Antengene selinexor myelofibrosis IND approved by China's National Medical Products Administration
SciSparc SCI-110 Alzheimer's disease and agitation approval received from the Israeli Ministry of Health and Helsinki Committee for a phase 2a trial
CytoSorbents ticagrelor cardiopulmonary bypass circuit during cardiothoracic surgery IDE approved by the FDA
Genentech intravenous Actemra (tocilizumab) COVID-19 in hospitalized adults and pediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation Emergency Use Authorization granted by the FDA
Galderma Restylane Contour cheek augmentation and midface contour deficiencies approved by the FDA
Jazz Pharmaceuticals Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) acute lymphoblastic leukemia or lymphoblastic lymphoma in pediatric and adult patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase approved by the FDA
Lupin Pharmaceuticals Solosec (secnidazole) trichomoniasis vaginalis approved by the FDA for expanded indication
Merck Keytruda (pembrolizumab) patients with locally advanced cutaneous squamous-cell carcinoma that is not curable by surgery or radiation approved by the FDA for expanded indication
Siemens Healthineers Magnetom
Free.Max 80 cm
lightweight magnetic resonance scanner cleared for marketing by the FDA
Bristol Myers Squibb Opdivo (nivolumab) plus Yervoy (ipilimumab) mismatch repair-deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy approved by the European Commission

 

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing